Foundayo is the fifth prescription drug to be authorized under the FDAs Commissioners National Priority Voucher program, through which the agency awards vouchers to drug developers whose work will address a health crisis in the United States, deliver more innovative cures, address unmet public health needs, and increase domestic drug manufacturing as a national security issue
Polex-Wolf J, Deibler K, Hogendorf WF, Bau S, Glendorf T, Stidsen CE, et al
Pros: FDA-approved, proven safety record Cons: Lower average weight loss in studies than retatrutide Tirzepatide Tirzepatide combines GLP-1 and GIP receptor targeting, offering around 21% weight loss and additional metabolic benefits
After your first month, consider PlexusDx's Precision Peptide Genetic Test to unlock personalized insights into your GLP-1 response patterns and metabolic pathways
We want to be best in market, says Vinjamoori, the chief medical officer